



<p>CERTIFICATE OF MAILING 37 C.F.R. §1.8</p> <p>I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date below:</p>	
<p><i>June 15, 2006</i> Date</p>	<p><i>Bonnie R. Smith</i> Signature</p>

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Stany DEPRAETERE
Katrien LORRÉ
Marie-Ange BUYSE

Serial No.: **10/550,175**

Filed: **September 21, 2005**

For: **TREATMENT OF TYPE 1 IMMUNE
RESPONSE-MEDIATED INFLAMMATORY
LUNG DISEASE BY MODULATION OF
IFN-GAMMA ACTIVITY**

§
§ Group Art Unit:
§
§ Examiner:
§
§ Atty. Dkt. No.: **11362.0043.PCUS01**
§
§
§
§
§
§

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR
APPLICATIONS DISCLOSING BIOLOGICAL SEQUENCES

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This response is made to the Notification, dated May 26, 2006, requiring Applicant to submit papers associated with applications containing biological sequences. Applicant respectfully indicates that the originally filed application does not directly disclose any nucleotide or amino acid sequence formulae. Therefore, Applicant believes that submission of the aforementioned papers is not required to place the application in condition for

examination on the merits. The Office is invited to contact the undersigned should there be any questions regarding this response.

A copy of the Notification is attached herewith.

Respectfully submitted,



Dennis R. Chesire
Reg. No. 57,452

Agent for Assignee
Innogenetics N.V.


Customer No. 23,369

HOWREY LLP
1111 Louisiana, 25th floor
Houston, TX 77002
(713) 654-7678 (Direct)

Date:

June 15, 2006

PCT



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/550,175	FIRST NAMED APPLICANT Stany Depraetere	ATTY. DOCKET NO. 11362.0043.PCUS01
---	---	---------------------------------------

23369
HOWREY LLP
C/O IP DOCKETING DEPARTMENT
2941 FAIRVIEW PARK DRIVE, SUITE 200
FALLS CHURCH, VA 22042-7195

INTERNATIONAL APPLICATION NO. PCT/EP04/50375	
I.A. FILING DATE 03/26/2004	PRIORITY DATE 03/28/2003

CONFIRMATION NO. 7536
371 FORMALITIES LETTER



Date Mailed: 05/26/2006

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/550,175	PCT/EP04/50375	11362.0043.PCUS01

FORM PCT/DO/EO/922 (371 Formalities Notice)